about
Understanding and applying pharmacometric modelling and simulation in clinical practice and researchLifespan based pharmacokinetic-pharmacodynamic model of tumor growth inhibition by anticancer therapeuticsIdentification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model.Human neutrophil kinetics: modeling of stable isotope labeling data supports short blood neutrophil half-lives.A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer.Clinical population pharmacokinetics and toxicodynamics of linezolid.Complex pattern of interleukin-11-induced inflammation revealed by mathematically modeling the dynamics of C-reactive protein.Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response modelsRelationships between sirolimus dosing, concentration and outcomes in renal transplant recipients.Pharmacokinetic/pharmacodynamic modelling in oncological drug development.A model qualification method for mechanistic physiological QSP models to support model-informed drug development.SEP enhanced the antitumor activity of 5-fluorouracil by up-regulating NKG2D/MICA and reversed immune suppression via inhibiting ROS and caspase-3 in mice.Lifespan based indirect response models.Review on modeling anti-antibody responses to monoclonal antibodies.A cell-level model of pharmacodynamics-mediated drug disposition.3D models of the hematopoietic stem cell niche under steady-state and active conditions.Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT.Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models.Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis.Transit and lifespan in neutrophil production: implications for drug intervention.A Mathematical Model of Granulopoiesis Incorporating the Negative Feedback Dynamics and Kinetics of G-CSF/Neutrophil Binding and Internalization.Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.General relationship between transit compartments and lifespan models.Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients.A semi-mechanistic model of CP-690,550-induced reduction in neutrophil counts in patients with rheumatoid arthritis.Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
P2860
Q28468334-6095C442-FBE2-47DD-A1F3-BE2A3E71C708Q28543966-AB74C53E-068F-44B8-A9D5-707FA4E17347Q30578482-87A88298-890E-4311-AB22-A8D41321F6A7Q31089324-B002F22C-2210-4182-A044-A3AB207C601AQ33402778-D0381733-227C-40F0-A304-06310746AFF4Q33413269-6383336E-A396-4D3B-873A-1EF10B7FBDCFQ33417707-3A23BD4B-8088-4510-B052-47CE2D21287DQ34580659-CB172D03-3399-46A5-B24C-27DD72566529Q35226129-0DA6BD45-01E6-4067-A3F1-F2CADD8FA09BQ35827212-56779A59-0599-48C8-AB1A-D3E11C5FDCE4Q36055576-43EE89BF-DE88-4DF0-87C6-931BAFF7C075Q36600060-D9249DF3-BF26-4094-97AA-25F356D93421Q37580265-D4211A79-8371-4FCF-90A0-1424942ABA17Q37972792-7AC702AF-C0C7-4F4F-B36D-8049EF6081F2Q38229813-747DD34F-F201-43C1-9E8B-DDEE21B63CE9Q39406092-7FB9C61F-4BBA-498A-B86D-F16412C0FB9CQ40965643-626CB2DD-CB68-474A-8292-B9EC14C7879BQ41987074-22CE45E8-4C37-405D-8387-805CA881074CQ42143847-8C322585-BAD0-43B0-B4DB-67317AE39342Q47103417-0A1C5216-D27F-47E2-AB2E-54BE8426090CQ47253570-2ED18EBB-EF3B-4B8D-BBFD-43C5E32FAB69Q50561543-E39B6681-C6E0-4695-8732-9BEF54BB71CCQ50878372-DBB473AB-290A-49A7-83DA-FD38DB77FE40Q51351388-E7C242E2-A767-4CB2-83FC-F85FF025D79FQ51681817-165F2F1A-2F37-4024-B3F0-E0A82CBE2611Q54712084-4813971C-AAE8-4C1A-9C20-AA602B758E69Q57106044-BFEE023F-D030-4596-86A2-02E57FAF6F6A
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Mechanistic models for myelosuppression.
@ast
Mechanistic models for myelosuppression.
@en
type
label
Mechanistic models for myelosuppression.
@ast
Mechanistic models for myelosuppression.
@en
prefLabel
Mechanistic models for myelosuppression.
@ast
Mechanistic models for myelosuppression.
@en
P356
P1476
Mechanistic models for myelosuppression.
@en
P2093
Lena E Friberg
Mats O Karlsson
P2888
P304
P356
10.1023/A:1023573429626
P577
2003-05-01T00:00:00Z
P6179
1017373225